For primary hyperlipidemia. ANDA 205977, held by Hetero Labs Ltd V. Pitavastatin Calcium.
As of Nov 16, 2026, ANDA 205977 (Pitavastatin Calcium), held by Hetero Labs Ltd V, was first approved by FDA on Apr 30, 2024, with 0 approved supplements and 0 published complete response letters.
Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 30, 2024 | Original application | Approved |
| Pitavastatin CalciumEQ 1MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 2MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 4MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters